China’s COVID-19 vaccine triggers an immune response – but is weaker in the 60s

China’s Synovac Coronavirus Vaccine Candidate Safely Triggers Antibodies to 90% of Firm’s Employees and Their Families – But Elderly People Have Weak Immune Reaction, Initial Testing Reveals

  • China on Monday reported positive preliminary results from tests with its coronavirus vaccine
  • Coronovirus antibodies significantly increased in 90% of test participants
  • Trials in more than 400 adults over 60 found that the pill did not cause significant side effects.
  • Elderly participants in the trial had slightly less strong immune responses to the vaccine, suggesting that it may not provide strong protection for them

Chinese firm Sinovac Biotech said on Monday that its coronavirus vaccine candidates appeared to be safe for older people, according to preliminary results from early to mid-stage testing, while the immune responses triggered by the vaccine were slightly weaker than in young adults.

Health officials are concerned about whether experimental vaccines can safely protect the elderly, whose immune systems typically react less strongly to vaccines, against the virus that caused around 890,000 deaths worldwide. is.

A Synovac media representative said, Synovac candidate Coronavac did not cause serious side effects in a combined Phase 1 and Phase 2 trials launched in May, including Liu Peicheng, a representative of Sinovac, aged at least 60.

The full results have not been published and have not been made available to Reuters.

This is when tensions between the US and China increase and the vaccine race increases. Despite the uneasy relationship between the two nations, President Trump has said that he will work closely with China to complete the coronavirus vaccine.

Researchers at Synovac told Reuters that the company’s experimental COVID-19 vaccine triggered an antibody response in 90% of test participants – but a weak one in the 60s

Four of the world’s eight vaccines are from China in the third phase of testing.

For the three groups of participants who took two shots of low, medium, and high-dose Coronavac, respectively, more than 90 percent of them experienced significant increases in antibody levels.

While the level was slightly lower than those seen in younger subjects, it was as expected, Liu said in a statement.

Elderly people are among the most populated by coronovirus, due to high rates of chronic disease, as well as a generally weak immune system.

This overall deterioration in their immune system also means that their immune responses, including vaccines, are weak – a phenomenon known as immunocranes.

Coronavac is already being tested in Brazil and Indonesia in last-stage human trials, already given to thousands of people to evaluate whether it is effective and safe to gain regulatory approval for large-scale use , Which includes about 90 percent of Synovac employees and their families, as part of China’s emergency vaccination plan to protect people facing high infection risk.

Potential vaccine storage may remain stable for up to three years, Liu said, which could introduce Synovac into vaccine distribution in some areas where cold-chain storage is not an option.

Such an estimate is contrasted with the fact that vaccine readings are in the acceptable range at 25 ° C (77 F) for 42 days, 28 days at 37 C (98.6 F), and 2–8 C (35.6–46.4). F) lasts for five months, Liu said. , Without disclosing complete data.

(Reporting by Roxanne Liu and Tony Munro; Editing by Lisa Shumaker)


Leave a Reply